Our Claim
We are a biotech company that specializes in developing novel therapies with focus on T cell responses.
Cutting-Edge Technology
At Belyntic, we utilize a modular approach to design and develop novel immunotherapeutic candidates.
Collaborate with Us
We believe in the power of partnerships to create impact and drive innovation in the biotech industry.
Innovative therapies to induce T cells to fight off infectious diseases & cancer
Belyntic stands at the forefront of medical innovation in vaccines, driven by our novel T-Fender platform technology, based on self-adjuvant, self-aggregating synthetic long peptides. Our therapeutic and prophylactic vaccines unleash potent and precisely targeted cellular immune responses, providing a robust defense against the reactivation of viral and bacterial infections. T-Fender vaccines are easily adaptable by the use of AI-based prediction technology, while their manufacturing and formulation is straightforward.
Key features of our vaccines
AI-Powered Development
Our use of AI-based prediction technology allows for the rapid design of novel vaccine candidates.
Strong cellular immunity
Our vaccines precisely induce pathogen-specific T cells with a lasting memory effect to protect vulnerable patients.
Stable Inherent Formulation
Our therapeutics form stable supramolecular structures with enhanced stability for facilitated application.
Belyntic at congresses and meetings
WVC – Barcelona,
October 2023
Meet Andreas and Oliver and engage on exciting topics around novel vaccine development.
Bio-Europe – Munich, November 2023
Andreas and Oliver are in Munich to connect and explore synergies with other drug developers.
AMR Conference – Basel, March 2024
Oliver will show a poster for new applications of T-Fender in the field bacterial infections.